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Abstract 
Angiogenesis, the formation of new blood vessels, is an essential aspect of, among others, embryonic development, 
wound healing and the female reproductive cycle. It is also necessary for the expansion of tumour masses beyond 
a minute volume. Acetylsalicylic acid (ASA) is a non-steroidal anti-inflammatory drug with additional antitumour 
activity. We tested ASA for its ability to inhibit angiogenesis in a simplified angiogenesis model, hASC+HUVEC co 
cultured in vitro, using immunocytochemical staining with fluorescence-marked antibodies and observation of tubule-
like structures and their branching under a fluorescence microscope. We confirmed that ASA is an efficient and useful 
angiogenesis inhibitor and deserves further attention. We intend using the designed angiogenesis model and the 
methods described for observing changes in angiogenesis after anti tumour photodynamic therapy (PDT), and also for 
enhancing PDT efficiency by addition of angiogenesis inhibitors. 
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Introduction 
Angiogenesis is the formation of new blood vessels. 
It is a multistep process, regulated by an interplay of 
pro- and anti-angiogenic factors involving endothelial 
cell proliferation, migration, differentiation, and tubule 
formation, as well as stabilization of newly-formed 
blood vessels. Angiogenesis is a critical aspect of 
essential physiological processes such as in embryonic 
development, wound healing, and the female 
reproductive cycle, as well as in pathological processes 
such as in tumor development, macular degeneration, 
rheumatoid arthritis, ischemic diseases, endometriosis 
and psoriasis [1-4]. 
Investigation of angiogenic mechanisms require 
assays that simulate the key steps in angiogenesis and 
provide tools for assessing the efficacy of therapeutic 
agents that either upregulate or down-regulate specific 
angiogenic mechanisms. The evaluation of factors that 
affect angiogenesis would optimally be studied in vivo 
due to complex interactions during angiogenesis. 
Despite the advantage of providing more information 
on complex cellular and molecular interactions 
compared to in vitro models, animal models have 
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several disadvantages (such as variability, animal-
specificity, and ethics). For this reason, human cell 
based assays in vitro would have more validity and 
extrapolation to humans. Although tubule formation in 
vitro does not cover the whole angiogenesis process, it 
effectively imitates the key steps (migration and 
differentiation of endothelial cells).Moreover, in vitro 
angiogenesis assays provide an opportunity to 
investigate angiogenic mechanisms and assess the 
efficacy of therapeutic agents with speed and simplicity 
that cannot be achieved using in vivo assays. The 
search for anti-angiogenic agents (mainly for the 
treatment of cancer) is particularly important at the 
current time. [1,3,4,5] 
Acetylsalicylic acid (ASA) is one of the non-
steroidal anti-inflammatory drugs (NSAIDs), widely 
used for the treatment of acute and chronic pain and 
inflammation. Studies [6-14] have shown that NSAIDs 
can reduce the risk of many types of cancer suggesting 
that these drugs may possess tumour-suppressive 
activity. Recent advances made in a number of 
laboratories have provided strong evidence that the 
anti-tumour activity of NSAIDs is associated with 
suppression of tumour angiogenesis. The formation of 
a vascular network in the tumour stroma (tumour 
angiogenesis) plays a critical role in tumour 
progression and metastasis formation. The absence or 
destruction of tumour-associated vasculature leads to 
tumour death via anoxia and lack of nutrients. Hence, 
inhibition of angiogenesis by NSAIDs may be an 
important way of combating cancer. [3,15,16] 
 
 
Experiments 
Our aim was to test ASA for its ability to inhibit 
angiogenesis on a simplified and improved 
angiogenesis model in vitro (designed by the scientific 
group from FICAM). 
For our experiments, we used cell lines hASC 
(human adipose stem cells, 22 000 cells/well) and 
HUVEC (human umbilical vein endothelial cells, 4 000 
cells/well) and treated hASC+HUVEC co-culture by 
acetylsalicylic acid (ASA) in a concentration 2, 1, 0.5, 
0.25 and 0.125 mmol/l. Further, we stained samples 
with a staining cocktail of 2 primary antibodies (anti-
von Willebrand factor, anti-Collagen) and subsequently 
by a staining cocktail of 2secondary antibody (anti-
rabbit IgG TRITC, anti-mouse IgG FITC). We then 
observed tubule-like structures and their branching 
under a fluorescence microscope Nikon Eclipse Ti and 
software NIS-Elements F 3.0. 
Fig 1B shows many tubules in the positive control, 
grown in the presence of growth factors and no tubules 
in the negative control grown in simple media without 
growth factors (Fig 1A).In the sample treated with the 
highest used ASA concentration, 2mM, fewer vessels 
can be seen(Fig 1F) whereas the sample with the 
lowest used ASA concentration, 0.125mM, (Fig 1C) 
looks similar to the positive control. Thus, 2 mM ASA 
appears to be effective but 0.125mM was not sufficient 
to inhibiti angiogenesis. 
We confirmed our prediction that ASA (mainly in a 
concentration of 2 mmol/l) is an efficient angiogenesis 
inhibitor and deserves our further attention. 
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Fig. 1: Formation of tubule-like structures by hASC+HUVEC co-culture incubated in (A) simple medium without 
??????? ???????? ???? ???????????????????????? ??????? ?????????????????????? ???? ??????????????????????? growth 
factors and 0.125mM ASA (D) stimulation medium with growth factors and 0.25mM ASA (E) stimulation medium with 
growth factors and 0.5mM ASA (F) stimulation medium with growth factors and 1mM ASA (G) stimulation medium 
with growth factors and 2mM ASA. Magnitude 100x. 
 
Conclusion 
Our group focus on testing photoactive substances 
called photosensitizers in vitrowhich in combination 
with visible light (photodynamic therapy - PDT) 
destroy cancer cells [17-27]. Search for and 
developmentof more efficient antitumour therapies is 
of paramount importance and PDT in particular is 
attracting much attention owing to its exceptional 
selectivity and specificity.Angiogenesis plays a critical 
role in tumour progression. Moreover,it is known that 
PDT combined with some photosensitiízers (such 
as Photofrin, Verteporfin, telaporfin, 5-aminolevulinic 
acid, NPe6, phthalocyanines and others) induces, 
besides direct cytotoxic effects, destruction of tumour-
associated vasculature which can lead to tumour death 
via lack of oxygen and nutrients [28, 29].  
It would be very interesting and useful to combine 
the experiences of both scientific groups and use the 
designed angiogenesis model for observing changes in 
angiogenesis, a major factor in cancer development, 
after PDT, and for enhancing PDT efficiency by 
addition of angiogenesis inhibitors.In the future, PDT 
in combination with antiangiogenic agents such 
as ASA will offer promising alternatives to currently 
used treatmentapproaches for malignant tumours, 
namely, radiotherapy, chemotherapy and surgery.  
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